Accessibility Menu
ALX Oncology logo

ALX Oncology(NASDAQ) ALXO

Market Cap$261.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-94%
5 Year-97%
1 Year+242%
1 Month-6%
$1.93
-1.03%
-0.02Today
After hours$1.94+$0.01 (+0.52%)
ALX Oncology last closing stock price
MetricPriceDate
Last closeUSD 1.942026-07-31
ALX Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.43%USD 2.032026-07-24
1 month-5.83%USD 2.062026-07-01
3 month+14.79%USD 1.692026-05-01
Year to date+71.68%USD 1.132025-12-31
1 year+241.85%USD 0.572025-07-31
3 year-67.45%USD 5.962023-08-01
5 year-96.69%USD 58.562021-07-30
Since inception-93.5%USD 30.002020-07-17

ALX Oncology Financials at a Glance

Market Cap

$261.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$88.87M

EPS (TTM)

-$1.49

P/E Ratio

-1.30

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$1.93

Volume

703,611.405

Open

$1.95

Previous Close

$1.94

Daily Range

$1.85 - $2.00

52-Week Range

$0.51 - $2.66

Estimated Earnings Date

Aug 11, 2026

ALXO News

Scientists happy

Why ALX Oncology Stock Is Skyrocketing Today

Keith SpeightsOct 3, 2023

ALXO: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ALX Oncology

ALX Oncology makes medicines that help the immune system kill cancer. These treatments help people fighting solid tumors and blood cancers. The company aims to extend patient lives through smart drug design.

Fighting Cancer With Smart Proteins

  • Evorpacept: A protein treatment that blocks the "don't eat me" signal used by cancer cells to hide from the immune system.
  • ALX2004: An antibody-drug conjugate, which is a medicine that delivers cell-killing drugs directly to cancer cells with specific growth receptors.
  • Pre-clinical Products: Early-stage research programs like ALTA-002 that test new ways to trigger immune responses against tumors.

Recent Moves and Partnerships

  • Completed a registered equity offering in February 2026 that raised $140.4 million in net proceeds for operations.
  • Dosed the first patient in the Phase 2 ASPEN-09-Breast clinical trial for metastatic breast cancer in January 2026.
  • Started a Phase 1 clinical trial for the drug candidate ALX2004 in August 2025 to treat tumors with specific markers.
  • Collaborated with Sanofi to study treatments for multiple myeloma, completing the dose escalation phase in August 2025.
  • Modified a gastric cancer study in November 2025 after identifying a specific protein as a key marker for patient response.

How ALX Tackles Tumors

ALX Oncology uses a unique inactive design for its drugs to reduce toxic side effects on healthy blood cells. This approach allows doctors to use higher doses and combine the treatment with other standard cancer medicines.

The Q1 2026 Scorecard

  • Net loss was $17.9 million in Q1 2026, improved 41.7% from $30.8 million in Q1 2025.
  • Operating loss reached $19 million in Q1 2026, improved 40.4% from $31.8 million in Q1 2025.
  • Research and development expenses were $13.6 million in Q1 2026, down 43% year-over-year.
  • Cash, cash equivalents, and investments totaled $169.1 million as of March 31, 2026.
  • Net cash used in operating activities was $18.6 million in Q1 2026, improved 24.4% from $24.7 million in Q1 2025.

Bottom Line

ALX Oncology has evolved from early research to mid-stage clinical testing of its lead cancer therapies. By securing new capital and focusing on specific biological markers, the company is working to make immune-based treatments more effective and less toxic.

AI Generated • May 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

43

CEO

Jason Lettmann, MBA

Website

www.alxoncology.com

Headquarters

South San Francisco, CA 94080, US

ALXO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-124.06%

Return on Capital

-333.42%

Return on Assets

-49.83%

Earnings Yield

-76.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$261.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

134.56M

Volume

703.61K

Avg. Volume

1.27M

Financials (TTM)

Gross Profit

-$150.00K

Operating Income

-$91.17M

EBITDA

-$86.70M

Operating Cash Flow

-$78.13M

Capital Expenditure

-$202.00K

Free Cash Flow

-$78.33M

Cash & ST Invst.

$140.32M

Total Debt

$5.22M

ALX Oncology Performance Analysis

ALX Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
ALX Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
ALX Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.0346.5%
20232023-12-31USD -3.7423.3%
20242024-12-31USD -2.58-30.9%
20252025-12-31USD -1.90-26.7%
ALX Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3015.5%
Q32025-09-3016.3%
Q42025-12-31-2.4%
Q12026-03-3121.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$150.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$261.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.07M

N/A

Employees

43

N/A

Net Income

-$17.93M

+41.7%

EBITDA

-$17.45M

+42.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$140.32M

+43.4%

Total Debt

$5.22M

-47.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$5.22M

+200.0%

Return on Assets

-49.83%

N/A

Return on Invested Capital

-57.65%

N/A

Free Cash Flow

-$18.70M

+24.4%

Operating Cash Flow

-$18.65M

+24.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTVArtiva Biotherapeutics, Inc.
$10.10-3.16%
STROSutro Biopharma, Inc.
$24.17-2.62%
IMUXImmunic, Inc.
$13.97-0.14%
RPTXRepare Therapeutics Inc.
$2.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ALXO

What is the current price of ALX Oncology?

ALX Oncology is trading at $1.94 per share.

What is the 52-week range for ALX Oncology?

Over the past 52 weeks, ALX Oncology has traded between $0.51 and $2.66.

How much debt does ALX Oncology have?

As of the most recent reporting period, ALX Oncology reported total debt of $13.05M.

How much cash does ALX Oncology have on hand?

ALX Oncology reported $32.28M in cash and cash equivalents in its most recent financial results.

What is ALX Oncology’s dividend yield?

ALX Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services